These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

341 related items for PubMed ID: 28540646

  • 21. Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders.
    Salcedo I, Tweedie D, Li Y, Greig NH.
    Br J Pharmacol; 2012 Jul; 166(5):1586-99. PubMed ID: 22519295
    [Abstract] [Full Text] [Related]

  • 22. Targeting the mTOR signaling network for Alzheimer's disease therapy.
    Wang C, Yu JT, Miao D, Wu ZC, Tan MS, Tan L.
    Mol Neurobiol; 2014 Feb; 49(1):120-35. PubMed ID: 23853042
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Glucagon-like peptide-1 protects hippocampal neurons against advanced glycation end product-induced tau hyperphosphorylation.
    Chen S, An FM, Yin L, Liu AR, Yin DK, Yao WB, Gao XD.
    Neuroscience; 2014 Jan 03; 256():137-46. PubMed ID: 24183963
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Dysregulated mTOR-dependent signaling in neurodegeneration or carcinogenesis: implication for Alzheimer's disease and brain tumors.
    Wang S, Wu J, Nie SD, Bereczki E, Pei JJ.
    J Alzheimers Dis; 2013 Jan 03; 37(3):495-505. PubMed ID: 23948902
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Modulation of GLP-1 signaling as a novel therapeutic approach in the treatment of Alzheimer's disease pathology.
    Tramutola A, Arena A, Cini C, Butterfield DA, Barone E.
    Expert Rev Neurother; 2017 Jan 03; 17(1):59-75. PubMed ID: 27715341
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. The development of non-peptide glucagon-like peptide-1 receptor agonist for the treatment of type 2 diabetes.
    Moon HS, Kim MK, Son MH.
    Arch Pharm Res; 2011 Jul 03; 34(7):1041-3. PubMed ID: 21811909
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. The mTOR Signaling Pathway in Myocardial Dysfunction in Type 2 Diabetes Mellitus.
    Suhara T, Baba Y, Shimada BK, Higa JK, Matsui T.
    Curr Diab Rep; 2017 Jun 03; 17(6):38. PubMed ID: 28434143
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.